Pressure to control pharmaceutical expenditure and price competition among pharmaceutical companies is fuelling the development of generic medicines markets in ambulatory care in Europe.
European generic prescribing trends and biosimilars
Generics/Research | Posted 29/07/2009 0 Post your comment
Professor Steven Simoens of the Katholieke Universiteit Leuven in Belgium wrote a special report aiming to identify, interpret and discuss the main supply and demand trends affecting the European generic medicines market in ambulatory care.
On the supply side, generic price-regulated systems and reference pricing systems are spreading across Europe.
On the demand side, European countries have attempted to stimulate demand for generic medicines by focusing on physician prescribing, generic substitution by pharmacists and patient copayments.
Finally, the development of biosimilars will probably become an important area of growth for the pharmaceutical industry over the next five years.
Source: Expert Rev Clin Pharmacol. 2008;1(4):497-503.
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Saudi FDA drug approvals and GMP inspections: trend analysis
Generic medications in the Lebanese community: understanding and public perception
Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
Comments (0)
Post your comment